trending

AstraZeneca Extends its Deal with ImpediMed

Mar 18, 2022

Key Takeaways:

  • AstraZeneca extends its second contract with ImpediMed to use SOZO for tracking patient fluid volume.
  • IPD expects to generate more than AU$5.5 million in revenue across the trials.
  • The Company has received positive feedback on SOZO.

ImpediMed Limited (ASX.IPD) shares are gaining attention following the announcement related to the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca.

By submitting your details and clicking on the button above, you agree to our Terms and Conditions, Privacy Policy and consent to receive marketing offers including to be contacted by email or phone. Before continuing, please read the Financial Services Guide available here.

Recent News

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions

Allow cookies